PL405648A1 - Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny - Google Patents

Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny

Info

Publication number
PL405648A1
PL405648A1 PL40564813A PL40564813A PL405648A1 PL 405648 A1 PL405648 A1 PL 405648A1 PL 40564813 A PL40564813 A PL 40564813A PL 40564813 A PL40564813 A PL 40564813A PL 405648 A1 PL405648 A1 PL 405648A1
Authority
PL
Poland
Prior art keywords
disease
diagnosing
patient
mir
vulnerability
Prior art date
Application number
PL40564813A
Other languages
English (en)
Inventor
Krystian Jażdżewski
Kinga Dymecka
Anna Wójcicka
Anna Kubiak
Wojciech Gierlikowski
Monika Maciąg
Monika Kolanowska
Agnieszka Czajka
Marta Kotlarek
Michał Śierniak
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Priority to PL40564813A priority Critical patent/PL405648A1/pl
Priority to PCT/IB2014/065342 priority patent/WO2015056195A1/en
Publication of PL405648A1 publication Critical patent/PL405648A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem wynalazku jest sposób diagnozowania raka wątroby i różnicowania raka wątrobowokomórkowego od przerzutów raka z jelita grubego do wątroby u pacjenta. Sposób obejmuje: - dostarczanie pochodzącej od pacjenta próbki biologicznej, - określenie ilości jednego lub więcej miRNA wybranego z grupy obejmującej miR-146a-5p, miR-125b-5p, miR-141-3p, miR-1269a w próbce biologicznej, - porównanie ekspresji miRNA z poziomem ekspresji miRNA otrzymywanym w grupie kontrolnej, w którym to sposobie u pacjenta diagnozuje się wystąpienie nowotworu i różnicuje jego podłoże, jeśli poziom ekspresji miRNA w próbce biologicznej jest zmieniony względem poziomu ekspresji obserwowanej w próbkach płynów biologicznych pochodzących od zdrowych pacjentów. Wynalazek dotyczy również zastosowania markera mikroRNA oraz zestawu zawierającego markery.
PL40564813A 2013-10-15 2013-10-15 Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny PL405648A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL40564813A PL405648A1 (pl) 2013-10-15 2013-10-15 Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
PCT/IB2014/065342 WO2015056195A1 (en) 2013-10-15 2014-10-15 Use of microrna markers for diagnosis of liver lesions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL40564813A PL405648A1 (pl) 2013-10-15 2013-10-15 Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny

Publications (1)

Publication Number Publication Date
PL405648A1 true PL405648A1 (pl) 2015-04-27

Family

ID=52827737

Family Applications (1)

Application Number Title Priority Date Filing Date
PL40564813A PL405648A1 (pl) 2013-10-15 2013-10-15 Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny

Country Status (2)

Country Link
PL (1) PL405648A1 (pl)
WO (1) WO2015056195A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081610A1 (en) * 2017-10-24 2019-05-02 Universite Paris Descartes DIAGNOSIS AND / OR PROGNOSIS OF HER2-DEPENDENT CANCER USING AT LEAST ONE MIRIK USED AS A BIOMARKER
WO2019204576A1 (en) * 2018-04-19 2019-10-24 The University Of Chicago Methods and kits for diagnosis and triage of patients with colorectal liver metastases
CN109182530A (zh) * 2018-11-05 2019-01-11 中国科学技术大学 肝细胞癌rna生物标志物
KR102275465B1 (ko) * 2019-01-18 2021-07-09 사회복지법인 삼성생명공익재단 전이성 대장암 치료물질 스크리닝 방법
CN110229899B (zh) * 2019-06-19 2024-04-09 广州医科大学附属第三医院 用于结直肠癌早期诊断或预后预测的血浆标记物组合
CN113755597B (zh) * 2021-10-14 2022-12-06 杭州师范大学 外周血外泌体miRNA联合标志物在制备检测HBV阳性肝硬化早期肝癌试剂盒中的应用
CN114990216B (zh) * 2022-05-31 2023-04-21 山东大学齐鲁医院 微小rna分子作为生物标记物在胆管癌预后中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214203A1 (en) 2002-12-12 2004-10-28 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
US20090186353A1 (en) * 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
US20060160114A1 (en) 2004-12-02 2006-07-20 Oncotech, Inc. Reagents and methods for predicting drug resistance
CN102943108B (zh) 2006-01-05 2014-05-21 俄亥俄州立大学研究基金会 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
US20080076674A1 (en) 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
US9096906B2 (en) * 2007-03-27 2015-08-04 Rosetta Genomics Ltd. Gene expression signature for classification of tissue of origin of tumor samples
US20100273172A1 (en) * 2007-03-27 2010-10-28 Rosetta Genomics Ltd. Micrornas expression signature for determination of tumors origin
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
EP2806273B1 (en) 2007-07-25 2017-09-06 University of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
WO2009143379A2 (en) 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Use of extracellular rna to measure disease
CA2728816A1 (en) 2008-06-27 2009-12-30 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Instit Ute For Biomedical Research Prediction of antiviral therapy response
EP3211098B1 (en) * 2008-11-10 2023-03-15 Battelle Memorial Institute Method utilizing microrna to determine physiological conditions
WO2010145035A1 (en) 2009-06-19 2010-12-23 Siu K W Michael Renal cell carcinoma biomarkers
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
US9598734B2 (en) * 2010-04-29 2017-03-21 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
CA2830301A1 (en) * 2011-03-18 2012-09-27 Baylor Research Institute Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis

Also Published As

Publication number Publication date
WO2015056195A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
PL406033A1 (pl) Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
PL405648A1 (pl) Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
PH12017501841A1 (en) Method for discriminating symptom of hepatic disease
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
MX2022012384A (es) Composiciones y metodos para cribar mutaciones en el cancer de tiroides.
BR112015011359A2 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
BR112012017084A2 (pt) métodos para previsão de resposta de câncer de mama triplo-negativo à terapia
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
WO2016138105A3 (en) Assays to determine dna methylation and dna methylation markers of cancer
BR112012032537A2 (pt) biomarcadores de câncer de pulmão e suas utilizações
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
BR112015026159A2 (pt) dispositivo de transferência de coleta de sangue
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
BR112014003877A2 (pt) biomarcadores de micro-rna e métodos de uso dos mesmos
EA201490946A1 (ru) Способ количественной оценки лечения рака
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
WO2014020444A3 (en) Methods and compositions for diagnosis and prognosis in breast cancer
BR112021016595A2 (pt) Método de diagnóstico ou prognóstico de câncer, métodos para diagnosticar câncer ou para triagem de câncer, para monitorar um indivíduo, para monitorar o tratamento de câncer, para avaliar a resposta de um indivíduo a um tratamento de câncer e para tratar um indivíduo com câncer detectado, kit e uso do kit
MY187655A (en) Use of nucleosome-transcription factor complexes for cancer detection
BR112015027249A2 (pt) método de diagnóstico de câncer